Abiopharma

🔍 Buller Richard E (Executive)

Company: Celcuity Inc. (CELC)

Report Date: 2026-05-04

Detailed Transactions and Holdings:

• Acquired 9,000 shares of Common Stock at $5.1 per share (Direct)
  Date: 2026-05-04 | Code: M | equity_swap_involved: 0 | shares_owned_after: 15,760.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 1,289 shares of Common Stock at $137.0 per share (Direct)
  Date: 2026-05-04 | Code: S | equity_swap_involved: 0 | shares_owned_after: 14,471.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 550 shares of Common Stock at $138.9955 per share (Direct)
  Date: 2026-05-04 | Code: S | equity_swap_involved: 0 | shares_owned_after: 13,921.00 | transaction_form_type: 4 | Footnotes: F1, F3, F2
• Sold 1,670 shares of Common Stock at $139.5832 per share (Direct)
  Date: 2026-05-04 | Code: S | equity_swap_involved: 0 | shares_owned_after: 12,251.00 | transaction_form_type: 4 | Footnotes: F1, F4, F2
• Sold 2,301 shares of Common Stock at $141.0271 per share (Direct)
  Date: 2026-05-04 | Code: S | equity_swap_involved: 0 | shares_owned_after: 9,950.00 | transaction_form_type: 4 | Footnotes: F1, F5, F2
• Sold 2,825 shares of Common Stock at $142.0358 per share (Direct)
  Date: 2026-05-04 | Code: S | equity_swap_involved: 0 | shares_owned_after: 7,125.00 | transaction_form_type: 4 | Footnotes: F1, F6, F2
• Sold 365 shares of Common Stock at $143.2378 per share (Direct)
  Date: 2026-05-04 | Code: S | equity_swap_involved: 0 | shares_owned_after: 6,760.00 | transaction_form_type: 4 | Footnotes: F1, F7, F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-05-04 | Code: H | shares_owned_after: 1,029.00
• Sold 9,000 shares of Stock Option (right to buy) at $5.1 per share (Derivative)
  Date: 2026-05-04 | Code: M | Expires: 2030-05-14 | equity_swap_involved: 0 | shares_owned_after: 654.00 | transaction_form_type: 4 | Footnotes: F1, F8, F2

Footnotes:

• F1: The sales and option exercise reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 8, 2025.
• F2: The Reporting Person and his spouse are the trustees and beneficiaries. The Reporting Person continues to beneficially own these securities held by the trust.
• F3: The price reported in Column 4 is a weighted average price. These shares of common stock of the issuer were traded in multiple transactions at prices ranging from $138.255 to $139.16, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
• F4: The price reported in Column 4 is a weighted average price. These shares of common stock of the issuer were traded in multiple transactions at prices ranging from $139.40 to $140.20, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
• F5: The price reported in Column 4 is a weighted average price. These shares of common stock of the issuer were traded in multiple transactions at prices ranging from $140.50 to $141.33, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
• F6: The price reported in Column 4 is a weighted average price. These shares of common stock of the issuer were traded in multiple transactions at prices ranging from $141.59 to $142.50, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
• F7: The price reported in Column 4 is a weighted average price. These shares of common stock of the issuer were traded in multiple transactions at prices ranging from $143.20 to $143.46, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
• F8: 100% vested.